

YOU ARE INVITED

Gilead Sciences invites you to a ZYDELIG[®] (idelalisib) educational event

Zydelig (idelalisib) Patient Case Study Review

ZYDELIG is FDA approved for 3 indications

Meeting Overview

- Review key details of FDA-approved ZYDELIG Prescribing Information
- Present design of key trials, efficacy profile, and safety profile
- Learn more about dosing and dose modifications

No CME credit is offered

Presented by:

ALAN PIERRE ZA SKARBNIK, MD
MD
JOHN THEURER CANCER CENTER

Date:

Wednesday, October 5, 2016
6:30 PM EST

Location:

Steakhouse 85
85 Church Street
New Brunswick, NJ
(732) 247-8585

Registration:

Please RSVP or e-mail by
10/02/2016 to:

Elizabeth McNamara at (973) 896-6756 or via email to liz.mcnamara@gilead.com

Please be aware that if you are a licensed US physician, any meal associated with this program is reportable under the Federal Open Payments/Sunshine Act. Gilead policy and the PhRMA Code on Interactions with Healthcare Professionals limit attendance at this promotional educational program to healthcare professionals. Accordingly, attendance by guests is not appropriate and cannot be accommodated.

Please see accompanying full Prescribing Information, including **BOXED WARNING**.



©2015 Gilead Sciences, Inc. All rights reserved. ZYDP0165 06/2015
ZYDELIG, ZYDELIG logo, GILEAD and the GILEAD logo are trademarks
of Gilead Sciences, Inc., or its related companies.

